JP2013538849A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538849A5
JP2013538849A5 JP2013531533A JP2013531533A JP2013538849A5 JP 2013538849 A5 JP2013538849 A5 JP 2013538849A5 JP 2013531533 A JP2013531533 A JP 2013531533A JP 2013531533 A JP2013531533 A JP 2013531533A JP 2013538849 A5 JP2013538849 A5 JP 2013538849A5
Authority
JP
Japan
Prior art keywords
naloxol
polyethylene glycol
mpeg
glycol conjugate
oxalate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013531533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538849A (ja
JP6034789B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2011/051161 external-priority patent/WO2012044243A1/en
Publication of JP2013538849A publication Critical patent/JP2013538849A/ja
Publication of JP2013538849A5 publication Critical patent/JP2013538849A5/ja
Application granted granted Critical
Publication of JP6034789B2 publication Critical patent/JP6034789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013531533A 2010-09-30 2011-09-29 結晶性ナロキソール−peg接合体 Active JP6034789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38850110P 2010-09-30 2010-09-30
US61/388,501 2010-09-30
PCT/SE2011/051161 WO2012044243A1 (en) 2010-09-30 2011-09-29 Crystalline naloxol-peg conjugate

Publications (3)

Publication Number Publication Date
JP2013538849A JP2013538849A (ja) 2013-10-17
JP2013538849A5 true JP2013538849A5 (enExample) 2016-02-18
JP6034789B2 JP6034789B2 (ja) 2016-11-30

Family

ID=45893441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013531533A Active JP6034789B2 (ja) 2010-09-30 2011-09-29 結晶性ナロキソール−peg接合体

Country Status (39)

Country Link
US (2) US9012469B2 (enExample)
EP (2) EP2992903B8 (enExample)
JP (1) JP6034789B2 (enExample)
KR (1) KR101791724B1 (enExample)
CN (1) CN103237547B (enExample)
AR (1) AR083268A1 (enExample)
AU (1) AU2011307608B8 (enExample)
BR (1) BR112013007113B1 (enExample)
CA (1) CA2812649C (enExample)
CL (1) CL2013000866A1 (enExample)
CO (1) CO6700851A2 (enExample)
CR (1) CR20130146A (enExample)
CU (1) CU24317B1 (enExample)
DK (1) DK2621496T4 (enExample)
EA (1) EA023929B1 (enExample)
EC (1) ECSP13012531A (enExample)
ES (2) ES2819305T3 (enExample)
GT (1) GT201300084A (enExample)
HR (1) HRP20151420T4 (enExample)
HU (1) HUE026726T2 (enExample)
IL (1) IL225308A0 (enExample)
ME (1) ME02313B (enExample)
MX (1) MX2013003587A (enExample)
MY (1) MY173890A (enExample)
NI (1) NI201300034A (enExample)
NZ (1) NZ609874A (enExample)
PE (1) PE20140636A1 (enExample)
PH (1) PH12013500561A1 (enExample)
PL (1) PL2621496T5 (enExample)
PT (1) PT2621496E (enExample)
RS (1) RS54488B8 (enExample)
SA (1) SA111320808B1 (enExample)
SG (1) SG188474A1 (enExample)
SI (1) SI2621496T2 (enExample)
SM (1) SMT201600004B (enExample)
TW (1) TWI518088B (enExample)
UA (1) UA112847C2 (enExample)
UY (1) UY33643A (enExample)
WO (1) WO2012044243A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2621496T2 (sl) 2010-09-30 2019-04-30 Astrazeneca Ab Kristalinični konjugat naloksol-PEG
CA2886276A1 (en) * 2012-10-30 2014-05-08 Nektar Therapeutics Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
CN107660207B (zh) * 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN107033155B (zh) * 2016-02-04 2019-04-26 国药集团国瑞药业有限公司 一种吗啡酮类化合物的立体选择性还原方法
EP3228307A1 (en) 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CN107303392A (zh) * 2016-04-19 2017-10-31 石家庄蒎格医药科技有限公司 一种聚乙二醇-纳洛酮组合物及应用
US11077103B2 (en) * 2016-11-23 2021-08-03 Aurobindo Pharma Ltd. Naloxegol oxalate and solid dispersion thereof
US11373198B2 (en) * 2016-12-02 2022-06-28 Honda Motor Co., Ltd. Evaluation device, evaluation method, and evaluation program
WO2019058387A1 (en) * 2017-09-19 2019-03-28 Msn Laboratories Private Limited, R&D Center IMPROVED PROCESS FOR THE PREPARATION OF (5Α, 6Α) -17-ALLYL-6- (2,5,8,11,14,17,20-HEPTAOXADOCOSAN-22-YLOXY) -4,5-EPOXYMORPHINANE-3,14-DIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
JP7690493B2 (ja) * 2020-05-04 2025-06-10 大鵬薬品工業株式会社 Iapアンタゴニスト化合物及びその中間体、並びにそれを合成する方法
CN114137133B (zh) * 2021-12-03 2023-06-09 北京尚修堂医药科技有限公司 一种纳洛醇-peg衍生物有关物质的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507136A (en) † 1949-02-19 1950-05-09 New York Quinine And Chemical Alkaloid purification
EP0668764A1 (en) * 1992-09-21 1995-08-30 QIN, Bo-yi Methods for identifying and using low/non-addictive opioid analgesics
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US20020182172A1 (en) 2000-11-30 2002-12-05 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
DE60122580T2 (de) 2000-12-22 2007-08-30 Smithkline Beecham P.L.C., Brentford 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidin-2,4-dion mesylatsalz
EP1362053B1 (en) 2001-02-20 2007-11-14 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
KR20050040832A (ko) 2001-10-29 2005-05-03 넥타르 테라퓨틱스 에이엘, 코포레이션 단백질 키나아제 c 억제제의 중합체 공액
DE60219677T2 (de) 2001-10-30 2008-05-15 Nektar Therapeutics Al, Corp., Huntsville Wasserlösliche polymerkonjugate von retinoesäure
LT2425821T (lt) * 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
NZ547168A (en) 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN1925875A (zh) 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
US8320574B2 (en) * 2006-04-20 2012-11-27 Hewlett-Packard Development Company, L.P. Methods and systems for reducing acoustic echoes in communication systems
ES2629766T3 (es) 2006-04-21 2017-08-14 Nektar Therapeutics Reducción estereoselectiva de una morfinona
JP2010509227A (ja) * 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル,コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
CN102014907A (zh) * 2008-05-07 2011-04-13 尼克塔治疗公司 外周作用阿片拮抗剂的口服给药
MX2012000980A (es) † 2009-07-21 2012-06-12 Nektar Therapeutics Conjugados de agonistas de oligómeros-opioides.
SI2621496T2 (sl) 2010-09-30 2019-04-30 Astrazeneca Ab Kristalinični konjugat naloksol-PEG

Similar Documents

Publication Publication Date Title
JP2021530565A5 (enExample)
JP2014501282A5 (enExample)
JP2020512316A5 (enExample)
JP2010516681A5 (enExample)
JP2012527442A5 (enExample)
JP2009537603A (ja) 5−アミノ−3−(2’,3’−ジ−O−アセチル−ベータ−D−リボフラノシル)−3H−チアゾロ[4,5−d]ピリミジン−2−オンのマレイン酸塩のA型及びB型結晶形
CN1227233C (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法
JP2010513494A5 (enExample)
RU2013145518A (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
JP2019504103A5 (enExample)
JP2012532106A5 (enExample)
JP2010519300A5 (enExample)
JP2013517320A5 (enExample)
JP2016510767A5 (enExample)
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
US10351574B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
JP2015512381A5 (enExample)
JP2013541589A5 (enExample)
JP2019524829A5 (enExample)
CN102875634A (zh) 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
JP2022553833A5 (enExample)
JP2023523165A5 (enExample)
JP2015531354A5 (enExample)
CA2794389A1 (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
RU2005105688A (ru) Полиморфизм додекагидроциклопента (а) фенантренилового эфира тиофенкарбоновой кислоты